Theralase Technologies Inc. V.TLT

TLD1433 World Class

[made2last]

Hi all;

Strong words by a brilliant scientist.

Dr. Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer of Theralase® stated, "The interim clinical data of Study II, to date, has proven to be world-class.

Thanks;

made2last

[Oilminerdeluxe]

If CR is obtained, then the patient has a 48.3%, 42.3% and 33.8% chance of remaining cancer free for 1, 2 and 3 years, respectively.

[enriquesuave]

Definitely "World Class". These are very solid results!  44% CR at 15 months and 46% TR. Basically 46% CR at 15 months! Basically the study has already achieved its objectives ( probably what the FDA outlined to company) IMHO. "Roger DuMoulin-White, B.E.Sc., P.Eng., Pro.Dir., President and Chief Executive Officer of Theralase® stated, "Based on the interim clinical

[Lesalpes29]

And what FDA will do now? AA pronto!

[Oilminerdeluxe]

That possible big investor, I hope he gets his/her cash in, asap. Looks like BTD application will be sent in Q3 which we are halfway through.  If so, very good. Finally. Just fix some money, Roger. 3 year 33% must be considered good. Sounds like TLT is destroying the competition at the speed of light. Hopefuly more info will follow at the CC in 9 days. 

[StevenBirch]

I hope so Oil, I always thought our life changing news would come in it's own news release and not part of a scheduled update. There can't be much holding them back now.

[Oilminerdeluxe]

This bit. "Theralase® has commenced receiving clinical data from the CSSs with a significant number of patients, who achieved CR, continuing to experience a duration of their CR beyond 450 days, with some patients demonstrating CR for up to 3 years and counting, post the primary Study Procedure." 'Has commenced receiving' sounds like they still need to wait for things. On

[Donein25]

This is the first occassion I recall of seeing "75 patients" mentioned as part of the enrollment plan...for years the plan has always been 100 patients at least. This change should not be underestimated! And it certainly could not have been made without some guidance from FDA. Very interesting.

[Gooseybear]

My biggest concern is the 3rd quarter 2026 FDA approval timeline and running out of cash.